Case series of BRAF‐mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. Issue 3 (11th November 2020)

• Record Type: Journal Article
• Authors: Fujimura, Taku; Yoshino, Koji; Kato, Hiroshi; Fujisawa, Yasuhiro; Nakamura, Yoshiyuki; Yamamoto, Yuki; Kunimoto, Kayo; Ito, Takamichi; Matsushita, Shigeto; Maekawa, Takeo; Ohuchi, Kentaro; Amagai, Ryo; Muto, Yusuke; Furudate, Sadanori; Kambayashi, Yumi; Hashimoto, Akira; Aiba, Setsuya
• Is Part Of: Journal of dermatology. Volume 48:Issue 3(2021)
• Page Start: 397
• Page End: 400
• Publication Date: 2020-11-11
• Subjects: adverse events, BRAF‐mutated advanced melanoma, efficacy, encorafenib plus binimetinib, second line; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.15688
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF ‐mutated advanced melanoma as second‐line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF ‐mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second‐line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first‐line targeted therapy. In contrast, overall survival and progress‐free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well‐tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second‐line therapy and beyond is comparable with that of first‐line targeted therapy.